MassDevice

Medtronic study highlights benefits of AI alerts ahead of TAVR treatment in heart valve disease

Medtronic (NYSE:MDT) today announced data from the ALERT trial aimed at addressing health disparities in structural heart care.
Tyler Morning Telegraph

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
MD&M East

Medtronic Breaks Out Strong TAVR Data at ACC

Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...
Reuters

Medtronic receives FDA approval for corevalve evolut pro transcatheter valve with advanced sealing

* Medtronic plc - 23 mm, 26 mm and 29 mm sizes of evolut pro system are available for use in united states Source text for Eikon: Further company coverage: ...
Reuters

Medtronic announces clinical study to evaluate its Corevalve Evolut pro system in 'everyday' clinical practice

* Says ‍announced a new post-market clinical study to evaluate its Corevalve Evolut Pro Valve in everyday clinical practice Source text for Eikon: Further company coverage: ...
Becker's Hospital Review

FDA approves Medtronic’s heart valve

Here are three things to know. 1. The heart valve is intended to treat patients with severe aortic stenosis who have a high or extreme risk for open heart surgery, according to a company news release.